Summary of the objective response rate (ORR) in the pembrolizumab cohort and chemotherapy cohort according to the baseline BMI and ΔBMI
| Objective response rate | ||||||
| Pembrolizumab cohort | χ2 test | Chemotherapy cohort | χ2 test | |||
| Response-ratio | ORR (%) (95% CI) | Response-ratio | ORR (%) (95% CI) | |||
| BMI (kg/m2) | ||||||
| Underweight (≤18.5) | 10/35 | 28.6 (13.7–52.5) | p=0.0077 p=0.0910* | 5/15 | 33.3 (10.8–77.8) | p=0.0758 p=0.3079* |
| Normal weight (18.5–25) | 201/467 | 43.0 (37.3–49.4) | 96/199 | 48.2 (39.1–58.9) | ||
| Overweight (25–30) | 97/232 | 41.8 (33.9–51.0) | 54/149 | 36.2 (27.2–47.3) | ||
| Obese (≥30) | 61/106 | 57.5 (44.0–73.9) | 29/57 | 50.9 (34.1–73.1) | ||
| ΔBMI | ||||||
| ≥1.4% | 116/173 | 67.1 (55.4–80.4) | p<0.0001 | 72/119 | 60.5 (47.3–76.2) | p<0.0001* |
| <1.4% | 227/548 | 41.4 (36.2–47.2) | 111/292 | 38.0 (31.2–45.8) | ||
*χ2 test for trend.
BMI, Body mass index.